TAF Launches Financial Aid Program Following FDA Approval of MPS IIIA Treatment
- Reports
- 5
- Developments
- 1
- Repetition
- 80%
New informationRepeats or wire copies
What happened
The Assistance Fund announced a new financial assistance program for individuals living with MPS IIIA-Sanfilippo A syndrome. This program was launched following the first-ever approval of a treatment for the condition by the FDA. The assistance is designed to help eligible people pay for out-of-pocket medical expenses, including copays, coinsurance, and deductibles.
From finanznachrichten.de
Why it matters
The FDA approval of a treatment for MPS IIIA-Sanfilippo A syndrome creates a need for financial support for families facing high medical costs. The Assistance Fund is providing this assistance to help manage the out-of-pocket medical expenses associated with the new treatment.
From finanznachrichten.de
Who's involved
- FDARegulatory agency that granted the first-ever approval of a treatment for MPS IIIA-Sanfilippo A syndrome
- TAFNonprofit organization that launched the financial assistance program for families
- National MPS SocietyNonprofit organization that serves the families receiving financial support from TAF
Keep exploring
The entities involved
- FDA
-
TAF
American nonprofit organization
Nothing else this week.
-
National MPS Society
nonprofit organization in Durham, United States
Nothing else this week.
Related events
- FDA approval enables commercial availability for a product associated with Indianapolis.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Matricelf Ltd. is seeking feedback from the FDA regarding its clinical trial design. The company is currently listed on the Tel Aviv Stock Exchange with plans for a dual listing to support its transition.
- FDA approval expands patient access to therapies for ACCORD.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.